JP2017511322A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511322A5
JP2017511322A5 JP2016559891A JP2016559891A JP2017511322A5 JP 2017511322 A5 JP2017511322 A5 JP 2017511322A5 JP 2016559891 A JP2016559891 A JP 2016559891A JP 2016559891 A JP2016559891 A JP 2016559891A JP 2017511322 A5 JP2017511322 A5 JP 2017511322A5
Authority
JP
Japan
Prior art keywords
conjugate
moiety
soluble polymer
water
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559891A
Other languages
English (en)
Japanese (ja)
Other versions
JP6728055B2 (ja
JP2017511322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023871 external-priority patent/WO2015153753A2/en
Publication of JP2017511322A publication Critical patent/JP2017511322A/ja
Publication of JP2017511322A5 publication Critical patent/JP2017511322A5/ja
Application granted granted Critical
Publication of JP6728055B2 publication Critical patent/JP6728055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559891A 2014-04-03 2015-04-01 Il−15部分とポリマーとのコンジュゲート Active JP6728055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03
US61/974,914 2014-04-03
PCT/US2015/023871 WO2015153753A2 (en) 2014-04-03 2015-04-01 Conjugates of an il-15 moiety and a polymer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020074680A Division JP2020114875A (ja) 2014-04-03 2020-04-20 Il−15部分とポリマーとのコンジュゲート

Publications (3)

Publication Number Publication Date
JP2017511322A JP2017511322A (ja) 2017-04-20
JP2017511322A5 true JP2017511322A5 (enExample) 2018-04-12
JP6728055B2 JP6728055B2 (ja) 2020-07-22

Family

ID=54241432

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016559891A Active JP6728055B2 (ja) 2014-04-03 2015-04-01 Il−15部分とポリマーとのコンジュゲート
JP2020074680A Withdrawn JP2020114875A (ja) 2014-04-03 2020-04-20 Il−15部分とポリマーとのコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020074680A Withdrawn JP2020114875A (ja) 2014-04-03 2020-04-20 Il−15部分とポリマーとのコンジュゲート

Country Status (12)

Country Link
US (1) US20170035898A1 (enExample)
EP (2) EP3139947B8 (enExample)
JP (2) JP6728055B2 (enExample)
KR (1) KR102432169B1 (enExample)
CN (1) CN106456716A (enExample)
AU (3) AU2015240806B2 (enExample)
CA (1) CA2942571C (enExample)
ES (1) ES2876433T3 (enExample)
IL (1) IL248169A0 (enExample)
MA (1) MA39711A (enExample)
MX (2) MX388865B (enExample)
WO (1) WO2015153753A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
JP7407511B2 (ja) 2015-10-08 2024-01-04 ネクター セラピューティクス IL-2Rβ選択的作動薬と長時間作用型IL-15作動薬との併用
JP2019503348A (ja) * 2015-12-21 2019-02-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−15組成物及びその使用
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN119700941A (zh) * 2017-05-15 2025-03-28 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
CN112004547A (zh) * 2018-02-26 2020-11-27 新索思股份有限公司 Il-15缀合物及其用途
MX2021005485A (es) * 2018-11-09 2021-06-18 Nektar Therapeutics Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
US20220193253A1 (en) * 2019-04-26 2022-06-23 Prolynx Llc Slow-release cytokine conjugates
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
US12344648B2 (en) * 2019-08-23 2025-07-01 Synthrox, Inc. IL-15 conjugates and uses thereof
CN117355337A (zh) * 2021-03-29 2024-01-05 奥迪曼药业科技有限公司 蛋白-大分子缀合物及其使用方法
BR112023027305A2 (pt) 2021-06-23 2024-03-12 Cytune Pharma Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
WO2023288226A2 (en) * 2021-07-12 2023-01-19 Nektar Therapeutics Polymer engineered forms of interferon-gamma and methods of use
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2025101551A1 (en) * 2023-11-06 2025-05-15 Regents Of The University Of Minnesota Prostate-specific membrane antigen (psma)-binding peptides and method of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE196315T1 (de) 1994-04-06 2000-09-15 Immunex Corp Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
DE60329627D1 (de) * 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
CA2509939C (en) 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polymer derivatives
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
TW200619227A (en) * 2004-08-11 2006-06-16 Hoffmann La Roche Mutant interleukin-15-containing compositions and suppression of an immune response
AU2005335217A1 (en) 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
PL2431741T3 (pl) * 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
EP3505186B1 (en) * 2010-07-30 2022-01-12 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
HRP20210642T1 (hr) * 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Similar Documents

Publication Publication Date Title
JP2017511322A5 (enExample)
JP2018510863A5 (enExample)
HRP20210642T1 (hr) Konjugati il-2 ostatka i polimera
JP2006519238A5 (enExample)
Wong et al. PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo
Sedlacek et al. Poly (2‐Oxazoline) s–Are They More Advantageous for Biomedical Applications Than Other Polymers?
Kloeckner et al. Gene carriers based on hexanediol diacrylate linked oligoethylenimine: effect of chemical structure of polymer on biological properties
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
WO2011112482A3 (en) Polymeric drug delivery conjugates and methods of making and using thereof
Heller et al. Directed Interactions of Block Copolypept (o) ides with Mannose‐binding Receptors: PeptoMicelles Targeted to Cells of the Innate Immune System
Abebe et al. Three‐layered biodegradable micelles prepared by two‐step self‐assembly of PLA‐PEI‐PLA and PLA‐PEG‐PLA triblock copolymers as efficient gene delivery system
JP2011528654A5 (enExample)
JP2011530597A5 (enExample)
Cunningham et al. New Design of Thiol‐Responsive Degradable Polylactide‐Based Block Copolymer Micelles
JP2011080089A5 (enExample)
JP2005520006A5 (enExample)
JP2013519636A5 (enExample)
ES2721850T3 (es) Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
JP2008533108A (ja) 生物学的に活性な分子の投与系としての、キトサンとポリエチレングリコールとのナノ粒子
WO2012054923A3 (en) Therapeutic nanoparticles with high molecular weight copolymers
ATE477291T1 (de) Präparate umfassend hyperverzweigte polymere
JP2019512006A5 (enExample)
JP2014503548A5 (enExample)
JP2014501765A5 (enExample)
Soni et al. Biodegradable block copolymers and their applications for drug delivery